Shots:

• The P-III BREEZE-AD7 study involves assessing of Olumiant (2mg- 4mg) + SOC topical corticosteroids vs PBO in patients with moderate to severe atopic dermatitis for 16wks. The P-II BREEZE-AD program is expected to be completed in 2019
• The P-III BREEZE-AD7 study results: met its 1EPs @16wks. i.e- (vIGA 0- 1) score of "clear or almost clear" skin (26%-34% vs 14.7%); EASI 75 (43.1%- 47.7% vs 25%); 4-point improvement in Itch NRS (38.1%- 44% vs 20.2%)
• Olumiant (qd) is a JAK inhibitor and is an approved therapy for mod. to sev. RA in adults is who have had an inadequate response to one or more TNF inhibitor therapies & DMARDs in the US & outside the US respectively

Click here to­ read full press release/ article

Ref: Eli Lilly | Image: Eli Lilly